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Introduction
Substantial racial/ethnic disparities in human immunodeficiency 
virus (HIV) infection exist in the United States (U.S.), and African 
Americans are disproportionately affected by HIV infection. As such, 
African Americans are important partners for HIV prevention research 
if we are to effectively reduce the burden of HIV in highly affected 
communities [1]. The National Institutes of Health (NIH) Revitalization 
Act established guidelines for the inclusion of racial/ethnic minorities 
in all NIH-supported human subjects research unless a compelling 
rationale is provided for their exclusion [2]. Yet, achieving adequate 
representation of minority and marginalized groups in clinical trials 
has sometimes been challenging and has resulted in ambiguous efficacy 
results [3]. For example, the first phase-III efficacy trial of an HIV 
vaccine, AIDSVAX B/B1, indicated the vaccine was not efficacious for 
preventing HIV infection [4,5]. However, the protective efficacy of 
AIDSVAX B/B was initially reported to be 66.8% among black, Asian, 
and mixed-race participants; and 78.3% among African Americans 
alone [4,5]. Because the majority of AIDSVAX trial participants were 
white (86%) and male (94%), the trial lacked adequate statistical power 
to address pertinent questions regarding vaccine efficacy, immunologic 
responses, and behavioral risk among racial/ethnic subgroups and 
women [4,5]. The recent RV-144 HIV vaccine regimen conducted in 
Thailand had a modest efficacy of 31% [6], but the sample was not 
designed to address any racial/ethnic differences. However, the RV-
144 trial has generated new enthusiasm for HIV vaccine researchers 
working with broadly neutralizing antibodies capable of neutralizing 
different HIV strains [7,8].
1AIDSVAX is an experimental preventive HIV vaccine that is made up of a synthetic 
copy of the surface protein of HIV called gp120. Because AIDSVAX is made up of 
synthetic or genetically engineered materials that lack all the elements required 
for infection, it cannot cause HIV infection. The vaccine that was tested in North 
America and Europe – AIDSVAX B/B – was designed to protect against subtype B, 
which is the HIV strain prevalent in those areas as well as Central America, South 
America, Australia and New Zealand.
Numerous barriers have been suggested that may preclude the 
participation of African Americans in clinical trials and human 
immunodeficiency virus (HIV) prevention research. These barriers 
have been categorized into four broad categories: 1) characteristics 
of potential participants, 2) health care system issues, 3) knowledge, 
perceptions, and attitudes toward HIV and research, and 4) personal and 
temporal factors related to clinical trial participation [9-16]. Barriers 
within these categories include low perceived risk and education, 
limited access to and utilization of health care, racial disparities in 
service delivery and location (e.g., hospital versus community clinic), 
language and cultural barriers, distrust of the medical establishment, 
lack of knowledge about clinical trials, and lack of incentive for research 
participation [9,17-20].
Although knowledge regarding clinical trials has not been shown 
to be positively related to willingness to participate (WTP) [14,21,22], 
educating individuals about the nature, purpose, and procedures of 
medical research is ethically essential and likely related to the successful 
recruitment of HIV clinical trial participants [23,24]. A lack of 
knowledge about HIV clinical trials has been documented in multiple 
communities [25,26], indicating the need to provide information, 
dispel misinformation, and to build trust among those communities 
targeted for trials. Increased understanding of the impact of trial-
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related information on WTP among African Americans will inform 
health education approaches tailored for HIV prevention trials.
Distrust of the medical establishment by African Americans 
has been ascribed in part to racist attitudes, theories, and practices 
of physicians in the early 1800s [27], and to the United States Public 
Health Service funded Tuskegee Study of Untreated Syphilis in the Negro 
Male [28], which has come to symbolize ethical misconduct in clinical 
research [28,29]. The Tuskegee Study, widely criticized for providing 
inadequate informed consent and medical treatment, is perhaps the 
most frequently cited factor for distrust of the medical establishment 
among African Americans, especially those in the southeastern United 
States [27,29-32]. In the context of HIV, genocidal conspiracy beliefs 
have been observed among moderate segments of the African American 
communities [33,34], and has been cited as a major barrier to HIV 
prevention among these communities [30]. While there is substantial 
literature suggesting that historical factors such as slavery and the 
Tuskegee Study may inhibit the participation of African Americans in 
clinical trials, other personal and temporally relevant factors may also 
be related to clinical trial participation. For example, altruism, perceived 
and actual risk of HIV infection, knowing someone who is HIV-infected 
or who has AIDS, the desire to protect oneself from HIV infection, 
perceived normative support for trial participation, and tolerance for the 
ambiguous nature of clinical trial participation (e.g., blinding, unknown 
efficacy, potential for vaccine-induced seropositivity) have been shown 
to be related to WTP in clinical trials [12,25,35-38]. Evaluating the 
relative contribution of negative historic events and distrust to WTP in 
trials, as well as the temporally relevant factors in the context of HIV, 
may provide a more comprehensive understanding of WTP among 
African Americans that can inform strategies for achieving diversity 
in future trials, improve the generalizability of results, and benefit the 
public health of African American communities. Although advances 
have been made in the evaluation of barriers to WTP in clinical trials, 
most studies have focused on a limited set of predictors. The objective of 
the present study was to evaluate the willingness of African Americans 
to participate in phase II HIV vaccine trials and to identify correlates of 
willingness to participate (WTP) among African Americans using an 
expanded group of predictors.
Methods
Participants
African American men and women living in three cities: 1-Jackson, 
Mississippi, 2-Washington, District of Columbia (DC), and 3-Oakland, 
California, were enrolled from November 2005 through July 2006 
and queried about issues related to willingness to participate in HIV 
vaccine trials. Background demographic and social data for the 3 
recruitment cities are shown in Table 1. Of note, each location had 
between 28%-79% African American populations and HIV prevalence 
rates of between 268 - 559 persons living with diagnosed HIV infection 
per 100,000 population (Table 1). Participants were recruited through 
convenience sampling at community events, beauty salons, and barber 
shops, block parties, bars, public parks, service organization venues, 
and community-based clinics across all 3 sites. Because the goal of 
the study was to evaluate the willingness of eligible African American 
participants to enroll in HIV vaccine trials, vaccine trial eligibility 
criteria were used to screen individuals for the study. Individuals 
were eligible if they self-identified as black or African American, or 
multiracial with black or African American heritage, and 18-70 years 
of age. Persons were also eligible if they were residents of one of the 
three study catchment areas, had not previously participated in a HIV 
vaccine trial, were HIV-seronegative and willing to be tested for HIV 
antibodies, and had not been diagnosed with cancer, active liver disease 
or illnesses requiring immunotherapy such as interferon or steroids.
Study instruments were administered on-site using 
AudioComputer-Assisted Self-Interview (ACASI) software (NOVA 
Research: Questionnaire Development System version 2.1; NOVA, 
1998). After individuals were determined to be eligible for the study, 
informed consent was obtained, and participants were oriented to the 
computerized interview. Participants completed a practice ACASI and 
addressed questions with study staff prior to initiating the survey. Staff 
members were available to answer questions during the interview. The 
ACASI included a section on WTP and predictors that are described 
in detail below. Institutional Review Boards at the Centers for Disease 
Control and Prevention, Jackson State University (Mississippi), the 
Whitman Walker Clinic (Washington, DC), and Independent Review 
Consulting, Inc (Oakland, CA) reviewed and approved this study 
protocol.
Instruments
Willingness to participate in HIV vaccine trials: To assess the 
influence of trial-related information on WTP in HIV vaccine trials, 
a computer-administered informed consent-like process presented 
information using a stepwise approach. Low risk and high risk among 
participants is defined below. Low-risk participants were presented 
information about phase-I HIV vaccine trials(i.e., phase-I trials are the 
first time a vaccine is given to people, are conducted to determine safety, 
usually involve about 100 people, require 12-18 months of follow-
up). Following the presentation, participants were asked about their 
WTP in phase-I trials. Similarly, low- and high-risk individuals were 
presented information about phase-II trials (i.e., if a vaccine appears 
to be safe in phase-I trials, phase-II trials are conducted to learn more 
about safety and protective responses in the body. Hundreds of people 
are needed for phase II trials which can last 2-3 years) [39]. After this, 
WTP was again assessed. Finally, high-risk individuals were presented 
information about phase-III trials (i.e., if phase-II trials indicate that a 
vaccine is safe and causes the body to react in a way that might protect 
against infection, then phase-III trials are conducted. Phase-III trials 
test to see if a vaccine protects people from HIV. Thousands of people 
at high risk for HIV are needed for phase-III trials, which can last 
from 3-5 years); [39] subsequently, WTP was again assessed. Because 
phase-II trials include both low and high risk participants, willingness 
Characteristic Jackson, MS Washington, DC Oakland, CA
Total population 173,514 601,723 390,724
African Americans 79.4% 50.7% 28.0%
Median household income $30,219 $66,583 $48,196
Employment 60.7% 69.0% 66.8%
Below poverty level 26.8% 13.9% 19.5%
Health insurance coverage 78.4% 94.1% 83.1%
HIV prevalence rate3 558.8 549.0 267.9
HIV vaccine trial experience4 No Yes No
1Centers for Disease Control and Prevention. HIV Surveillance Report, 2011; 
vol. 23. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published 
February 2013.Accessed August 27, 2014.
2United States Census 2010.  2010 Census Interactive Population Search. http://
www.census.gov/2010census/popmap/ipmtext.php?fl=28.  Accessed August 27, 
2014.
3Persons living with diagnosed HIV infection, year-end 2010. Rates are per 
100,000 population.
4ClinicalTrials.gov. http://clinicaltrials.gov/ct2/help/how-use-search-results.  Ac-
cessed August 27, 2014.
Table 1:  Demographic and social characteristics1, 2 of the 3 U.S. cities from which 
persons were enrolled for African Americans’ willingness to participate in HIV 
vaccine trials study.
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to participate in phase-II trials was the outcome variable in the WTP 
analyses for the current study.
HIV risk behavior: Participants were asked with how many 
HIV-infected, HIV-uninfected, and HIV-unknown serostatus men 
and women they had sex with in the three months prior to study 
enrollment, along with questions on frequency of sex and condom 
use. Participants were also asked if they had sex with anyone known 
to have had a sexually transmitted infection (STI) or injected drugs; 
had a sexually transmitted infection themselves; or exchanged sex for 
money, drugs, or shelter. Women were also asked if they recently had 
sex with a man who had been in prison. Participants also responded to 
questions on injected drug use and crack cocaine smoking. Participants 
were classified to be at low risk of HIV infection if they were in a 
mutually monogamous relationship with an HIV-uninfected partner 
during the past year or did not report any of the following: smoked 
crack, exchanged sex for money or drugs; had sex with more than two 
partners and reported infrequent condom use; had sex with another 
man (men only); had sex with a HIV-infected partner, injecting drug 
user, a partner with a recent sexually transmitted infection or who had 
recently been in prison (women only). Any participant reporting any of 
the preceding behaviors or circumstances were classified as high risk. 
Sexual identity: Participants responded to a series of questions on 
sexual identity as well as gender of sex partners. Men were categorized 
as “men who have sex with men” (MSM) if they self-identified as 
homosexual, MSM, or reported having sex with another man in the 
past 3 months.
Access to medical care: Participants indicated the extent to which 
they had access to medical care by selecting one of the following: (a) I 
have all the medical care that I need, (b) I have good medical care but 
not all that I need, (c) My access to medical care is very limited, (d) I 
rarely get good medical care, and (e) I have no access to medical care.
Knowledge of clinical trials, HIV vaccine trials, and the tuskegee 
syphilis study: To assess knowledge of clinical trials generally and HIV 
vaccine trials, 17 questions were administered (True/False/Don’t know) 
addressing the purpose of trials, informed consent, representation of 
African Americans in trials, HIV antibody testing requirements, risk 
of infection from study vaccine, and the need to practice safe sex if 
in a trial. Participants were also asked if they had ever heard of the 
Tuskegee Syphilis Study (Yes/No) and if so, seven additional questions 
were administered regarding specific knowledge about the study (True/
False/Don’t know).
Multidimensional vaccine attitude inventory (MVAI): A subset 
of the MVAI (14 items) was used to measure four constructs previously 
shown to be related to WTP in HIV vaccine trials [36]. The constructs 
assessed include genocidal conspiracy beliefs (3 items, α=0.78), perceived 
decreased risk of HIV infection (4 items, α=0.78), altruism (3 items, 
α=0.72), and Tolerance for the ambiguous nature of trials (4 items, 
α=0.78). For all items, participants responded using a 5-point Likert-
type scale.
Barriers to research participation questionnaire (BRPQ): A 
17-item instrument developed by Kibler and Brisco [40] was used 
to measure five constructs that may be associated with WTP in HIV 
prevention trials [9]. The constructs assessed by the BRPQ include 
mistrust toward researchers’ motives and government sponsorships 
of research, incentives for participation, role overload (perception of 
serving in multiple social or occupational roles), religious beliefs that 
may be inconsistent with participation in scientific research, and health 
beliefs that could affect sentiments toward research. Psychometric 
examination of the BRPQ has indicated support for the five factors 
through confirmatory factor analysis, as well as good three-week test–
retestreliability (r=0.80) and marginal internal consistency (α=0.63) 
[40]. The BRPQ uses a five-point Likert type scale for responses. 
Knowing someone with HIV/AIDS and social support for trial 
participation: Participants were asked if they knew anyone who was 
infected with HIV or who had AIDS (2 questions). Social support for 
trial participation was assessed by combining three 5-point Likert-type 
items addressing whether friends, family, and sexual partners would 
support their decision to participate in HIV vaccine trials (α=0.91). 
Perceived risk of HIV infection: Perceived risk was assessed 
using three Likert-scale response questions:1-“How likely do you 
think it would be for you to become infected with HIV in the next 5 
years?”; 2-“Do you believe that you are at low, medium, or high risk for 
becoming HIV infected?”; and 3-“My current sexual partner(s) place 
me at-risk of becoming infected with HIV.” Responses to the questions 
were summed to derive an index score of perceived HIV risk.
Data analyses
Chi-square tests of independence for categorical variables and one-
way analysis of variance for continuous variables were utilized to compare 
participants in three US cities on demographic variables. Because the 
dependent variable, WTP in HIV vaccine trials, is an ordered response 
variable, ordinal regression analyses were employed to assess the 
correlates of each independent variable to WTP in HIV vaccine trials. 
Initially, the bivariate relationships of the covariates to WTP in HIV 
vaccine trials were assessed by conducting separate ordinal regression 
analyses for each independent variable: HIV risk, sexual identity, study 
site, access to health care, knowledge about clinical trials, knowledge 
of HIV vaccine trials, awareness of the Tuskegee syphilis study, HIV/
AIDS genocidal conspiracy, mistrust, knowing someone with HIV/
AIDS, social network support for trial participation, perceptions of 
HIV risk, perceived protection in trial participation, altruism, incentive 
for trial participation, role overload, tolerance for ambiguity, religious 
beliefs precluding research participation, and health beliefs precluding 
research participation. Independent variables that were significantly 
related to WTP in the bivariate analyses (p<0.05) were retained for the 
multivariable analyses. Positive beta coefficients indicated a positive 
association with WTP, and negative beta coefficients indicated a 
negative association with WTP.
Results
Of 1,859 individuals screened for the study, 1,665 (89.6%) were 
eligible to participate. Reasons for ineligibility included HIV infection 
(3.7%); a health condition other than HIV that would result in 
ineligibility for an actual HIV vaccine trial (2.6%); living outside of a 
study site catchment area (2.8%); participation in a previous HIV vaccine 
trial (0.7%); not being of black or African American descent (0.6%); 
unwilling to test for HIV antibodies and thus not eligible to participate 
in an actual trial (0.3%); and not meeting the age requirements for 
participation (0.3%). Valid and complete ACASI records were obtained 
from 1,452 (87.2%) of the 1,665 eligible individuals. 
Descriptive results
Participant characteristics are summarized in Table 2. There 
were significant differences in age across the three study sites with 
participants in Oakland being the oldest and Jackson being the youngest 
(p<0.01). Of note, most participants reported ≤ high school education, 
with those from Oakland being the least likely to have completed high 
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school (p<0.01). Approximately half of participants reported an income 
of <$10,000 per year, with those from Oakland reporting lower income 
than participants from the other sites (p<0.01). While the majority of 
the participants were single, more participants from Jackson reported 
being married (p<0.01). Overall, self-reported HIV risk behavior was 
similar across sites. However, participants from Oakland were more 
likely to report smoking crack cocaine (p<0.01), DC participants 
reported a higher rate of having sex with partners who injected drugs 
(p<0.05), and those from Jackson were more likely to report having had 
an STI (p<0.05). 
Predictor variables
Knowledge about clinical trials was fairly good; 76.6% of the 
questions about clinical trials were answered correctly (Table 3). 
Study Site
Variable Jackson, MS(n = 570)
Washington, DC
(n = 543 )
Oakland, CA
(n = 339) p
†
Mean Age (SD) 30.2 ±10.1 36.7 ± 12.3 40.7 ± 11.6 <0.01
Education
  <High school
  High school
  College graduate
  Graduate School 
16.1%
63.8%
16.3%
3.7%
15.7%
74.6%
7.6%
2.2%
27.8%
61.5%
9.5%
1.2%
<0.01
Marital Status
  Single
  Married
  Divorced, Separated,   
 or Widowed
76.5%
14.4%
9.2%
72.4%
9.2%
18.4%
72.3%
9.7%
18.0% <0.01
Income
  <$10,000
  $10,000 - $19,999
  $20,000 - $34,999
  $35,000 -$49,999
  ≥ $50,000
45.3%
19.6%
18.8%
10.0%
6.4%
43.1%
13.6%
20.1%
13.6%
9.5%
64.6%
18.6%
5.6%
7.1%
4.2%
<0.01
Injected drugs 3.2% 5.7% 5.3% NS
Smoked crack cocaine 8.4% 10.3% 25.7% <0.01
Sex partner had STI 5.9% 6.0% 3.7% NS
Sex with IDU 3.9% 7.8% 5.3% <0.05
Had STI 6.5% 3.8% 3.0% <0.05
Exchanged sex for drugs or money 8.4% 12.3% 9.8% NS
Sex partner recently in jail (women only) 20.3% 18.6% 24.7% NS
Note. STI - sexually transmitted infection; IDU - injecting drug user; NS - non-significant; SD-standard deviation; †χ2 test of independence
Table 2:  Demographic and HIV risk characteristics of African Americans enrolled from three U.S. cites. (n=1,452).
Variables Statistics Scale
Participant characteristic 
   HIV Risk 
    Low
    High
Sexual Identity
      Heterosexual men
      Men who have sex with men
      Heterosexual women
53.0%
47.0%
21%
20%
59%
Percent of Participants
Percent of Participants
Healthcare system issue
   Adequate healthcare access 
Knowledge, perception, and attitude toward HIV and Research
   Knowledge about clinical trials
   Knowledge about HIV vaccine trials
   Awareness of the Tuskegee Syphilis Study
HIV/AIDS genocidal conspiracy 
Mistrust
Personal and temporal factors related to clinical trial participation
   Know someone infected with HIV/AIDS
Social network support for trial participation 
Perceptions of HIV Risk 
perceived protection in trial participation
  Altruism 
   Incentive for participation 
   Role overload (serving in multiple social or occupational roles)
   Tolerance for ambiguity 
   Religious beliefs precluding research participation 
   Health beliefs precluding research participation 
2.3 ± 1.2a
76.6%
66.4%
41.4%
2.8 ± 1.1a
3.1 ± 0.8a
55.9%
3.2 ± 0.5 a
1.6 ± 0.6a
2.7 ± 0.8a
3.4 ± 0.8a
3.1 ± 0.4a
2.4 ± 1.0a
3.1 ± 0.8a
3.3 ± 0.9a
2.0 ± 0.7a
1=Complete Access, 5=No Access
Percent Correct Responses
Percent Correct Responses
Percent of Participants
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree
Percent of Participants
1=Strongly Disagree, 5=Strongly Agree
1=Low Risk, 4=High Risk
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree
1=Strongly Disagree, 5=Strongly Agree 
Note. a=Mean+SD
Table  3: Summary scores of predictor variables for African Americans’ willingness to participate in HIV vaccine trials enrolled from three U.S. cites. (n=1,452).
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Participants were less familiar with HIV vaccine trials with 66.4% of 
these questions being answered correctly. The vaccine trial concepts 
most misunderstood, indicated by incorrect or “don’t know” responses 
included: (1) the purpose of HIV vaccine studies is to find a cure (86%), 
(2) minorities are over-represented in HIV vaccine trials (55%), (3) 
a preventive vaccine may stop an individual from becoming infected 
with HIV (48%), (4) trial participants are encouraged to engage in 
high-risk behavior (40%), and (5) a vaccine has already been developed 
that prevents HIV infection (36%). More than one-half (58.6%) of 
study participants had not heard of the Tuskegee Syphilis Study. 
Results concerning participant attitudes toward scientific research 
and mistreatment of African Americans, participant characteristics, 
healthcare system issue, and personal and temporal factors related to 
clinical trial participation are also depicted in Table 3.
Willingness to participate in Phase II vaccine trials
The data revealed 7.6% of the participants indicated they were 
definitely, 19% probably, 31.4% might be, and 42% not at all WTP 
in vaccine trials. Although there were demographic and HIV risk 
characteristic differences among participants across the three study 
sites, participants did not differ in WTP across study sites. 
Bivariate and multivariable analyses
Bivariate analyses revealed that greater WTP was associated with 
higher HIV risk, less healthcare access, greater knowledge of HIV 
vaccine trials, less belief in the HIV genocidal conspiracy, less mistrust 
of the government and research, knowing someone infected with 
HIV, stronger social network support for trial participation, greater 
perception of risk, greater perceived protection in trial participation, 
greater altruism, less role overload, and tolerance for ambiguity 
(ps<0.01). These significant correlates were entered in the multivariable 
ordinal regression analysis (Table 4). Nine variables emerged as 
independent predictors of greater WTP in Phase II vaccine trials: 
higher HIV risk (p<0.01), inadequate healthcare access (p<0.01), less 
belief in HIV/AIDS genocidal conspiracy (p<0.01), less mistrust of 
government and research (p<0.01), greater social network support for 
trial participation (p< 0.01), greater perceptions of HIV risk (p< 0.05), 
greater perceived protection in trial participation (p<0.01), greater 
altruism (p<0.01), and greater tolerance for ambiguity (p<0.01) (Table 
4). Marginal significance was observed for knowing someone with 
HIV/AIDS (p=0.06).
Discussion
This study assessed the willingness of African American men and 
women at low and high risk of HIV infection to participate in HIV 
vaccine trials. This study adds to previous literature by evaluating a 
comprehensive set of correlates, including: 1) participant characteristics, 
2) health care system issues, 3) knowledge, perceptions, and attitudes 
toward HIV and research, and 4) personal and temporal factors related 
to clinical trial participation. The results suggest all four domains 
contribute to WTP in vaccine trials among African Americans.
As others have indicated, high-risk participants reported greater 
WTP in vaccine trials [9,41]. Participants with less healthcare access 
also reported more WTP. These results are likely due to the perceived 
health benefit of trial participation. Consistent with the literature [9], 
historic distrust variables were generally related to WTP, with mistrust 
and the belief in HIV genocidal conspiracy providing independent 
negative associations with WTP. Among the four domains assessed, 
variables likely to be temporally and personally relevant to individuals 
in the context of HIV emerged as the stronger predictors of WTP. 
Altruism was the most prominent factor related to WTP, suggesting 
that helping one’s community improve the health of its residents was 
the strongest motivator for trial participation. Social support for trial 
participation, perceived behavioral risk of HIV infection, perceptions 
of decreased risk if enrolled in a trial, and intolerance for the ambiguous 
nature of trials also showed strong association with WTP in Phase- II 
vaccine trials.
These findings indicate that, while there has previously 
been suspicion by some that African Americans might be used 
inappropriately in HIV-related research [42], such negative feelings 
were not as prominent among these study participants. Trial sponsors 
interested in achieving racial and ethnic diversity in future HIV 
vaccine research should incorporate strategies that appeal to altruistic 
motivations to help one’s community, educate individuals as to their 
risk of HIV infection, mobilize the community to provide a supportive 
environment for vaccine trial participation, develop educational and 
consent processes that minimize the ambiguity associated with trial 
participation (blinding, unknown efficacy, potential for social harm, 
potential social reactions, HIV testing), and partner with HIV-infected 
individuals who may want to appeal to their friends and community 
to participate in HIV vaccine trials [13]. Popular opinion leaders, 
including public figures who are HIV infected and willing to disclose 
their status while they appeal to other African Americans to participate 
in HIV research and HIV vaccine trials might also help to increase 
ethnic diversity in future trials [13]. 
Our study had some notable limitations. While the sample size 
in this study far exceeded that of previous studies evaluating the 
willingness of African Americans to participate in HIV-related clinical 
trials, our non-probability sample precludes the generalization of these 
findings to other diverse African American communities. However, 
the lack of differences in WTP across study sites demonstrates the 
possibility that willingness may not vary by geographic location. 
Additionally, the evaluation of WTP in a hypothetical HIV vaccine trial 
may not accurately reflect actual enrollment in trials as pointed out by 
Buchbinder et al. [25]. However, WTP in hypothetical trials has been 
shown to be a strong predictor of enrollment in actual trials [21]. Also, 
our data were collected some years ago. However, more recent HIV 
vaccine WTP studies have similarly concluded that African Americans 
are willing to be engaged in this research, given appropriate cultural 
context [13,41] and even community liaison programs [43].
Despite the limitations, a major advantage of this study was that 
Variables β Standard error p value
HIV Risk .42 .11 <0.01
Adequate healthcare access .12 .05 <0.01
Knowledge about HIV vaccine trials .01 .01 .581
HIV/AIDS genocidal conspiracy -.24 .06 <0.01
Mistrust -.07 .01 <0.01
Know someone infected with HIV .20 .11 .059
Social network support for trial participation .58 .12 <0.01
Perception of HIV Risk .20 .09 <0.05
Perceived protection in trial participation .36 .07 <0.01
Altruism 1.14 .09 <0.01
Role overload(serving in multiple social or 
occupational roles) -.09 .05 .096
Tolerance for ambiguity -.43 .07 <0.01
Note. Model 2 = 494.89 (p <.001)
Table  4: Ordinal regression analysis with significant predictors of willingness to 
participate in vaccine trials for African Americans enrolled from three U.S. cites. 
(n=1,452).
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it evaluated participant characteristics, healthcare access, historic 
distrust variables, as well as those that may be more personally and 
temporally relevant to the individual in the context of HIV. Although 
not a significant predictor in our study, the Tuskegee Study legacy and 
distrust of researchers/medical establishment are important factors 
that cannot be ignored when planning and conducting HIV prevention 
research and programs in African American communities [33]. In 
addition to building trust, emphasis on temporally-relevant contextual 
factors related to personal HIV experiences, including knowledge of 
someone with HIV, and community support for vaccine trials, may 
provide an effective strategy for engaging African Americans in HIV 
vaccine trials and working toward reduced HIV-related disparities.
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